Anticancer activity of bicalutamide-loaded PLGA nanoparticles in prostate cancers

Guo,Jun; Wu,Shu‑Hong; Ren,Wei‑Guo; Wang,Xin‑Li; Yang,Ai‑Qing

doi:10.3892/etm.2015.2796

Anticancer activity of bicalutamide-loaded PLGA nanoparticles in prostate cancers

Authors:
- Jun Guo
- Shu‑Hong Wu
- Wei‑Guo Ren
- Xin‑Li Wang
- Ai‑Qing Yang
View Affiliations

Affiliations: Department of Urology, The Affiliated Hospital of Taishan Medical University, Taian, Shandong 271000, P.R. China, Department of Urology, Feicheng Kuangye Central Hospital, Feicheng, Shandong 271608, P.R. China, Department of Urology, Rugao Boai Hospital, Nantong, Jiangsu 226500, P.R. China, Department of Pathology, The Affiliated Hospital of Taishan Medical University, Taian, Shandong 271000, P.R. China, Department of Pathology, The First People's Hospital of Taian, Taian, Shandong 271000, P.R. China
Published online on: October 14, 2015 https://doi.org/10.3892/etm.2015.2796
Pages: 2305-2310

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Prostate cancer is the most commonly diagnosed non-cutaneous malignancy in men in western and most developing countries. Bicalutamide (BLT) is an antineoplastic hormonal agent primarily used in the treatment of locally advanced and metastatic prostate cancers. In the present study, the aim was to develop a nanotechnology‑based delivery system to target prostate cancer cells. This involved the development of a BLT‑loaded poly(D,L‑lactide‑co‑glycolide) PLGA (PLGA‑BLT) nanoparticulate system in an attempt to improve the therapeutic efficacy of BLT in prostate cancer and to mitigate its toxicity. Nanosized particles with a uniform size distribution and spherical shape were developed. PLGA‑BLT showed a pronounced cytotoxic effect on LNCaP and C4‑2 cancer cells. The superior cell‑killing effect of the nanoparticles may be attributable to their sustained drug‑release characteristics and high cellular internalization. PLGA‑BLT was also found to significantly inhibit colony formation in the two cell lines. Furthermore, the caspase‑3 activity of PLGA‑BLT treated cancer cells was enhanced, indicating the cell apoptosis‑inducing potential of PLGA‑BLT. Overall, these results suggest that nanotechnology‑based formulations of BLT exhibit superior anticancer activity and have enormous potential in the treatment of prostate cancers.

View Figures

View References

1	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
2	Gianino MM, Galzerano M, Minniti D, Di Novi C, Martin B, Davini O and Barbaro S: A comparative costs analysis of brachytherapy and radical retropubic prostatectomy therapies for clinically localized prostate cancer. Int J Technol Assess Health Care. 25:411–414. 2009. View Article : Google Scholar : PubMed/NCBI
3	Snyder CF, Frick KD, Blackford AL, Herbert RJ, Neville BA, Carducci MA and Earle CC: How does initial treatment choice affect short-term and long-term costs for clinically localized prostate cancer? Cancer. 116:5391–5399. 2010. View Article : Google Scholar : PubMed/NCBI
4	Li J, Djenaba JA, Soman A, Rim SH and Master VA: Recent trends in prostate cancer incidence by age, cancer stage, and grade, the United States, 2001–2007. Prostate Cancer. 2012:691382012. View Article : Google Scholar
5	Niraula S and Tannock IF: Broadening horizons in medical management of prostate cancer. Acta Oncol. 50(Suppl 1): 141–147. 2011. View Article : Google Scholar : PubMed/NCBI
6	Sowery RD, So AI and Gleave ME: Therapeutic options in advanced prostate cancer: Present and future. Curr Urol Rep. 8:53–59. 2007. View Article : Google Scholar : PubMed/NCBI
7	Mishra B, Patel BB and Tiwari A: Colloidal nanocarriers: A review on formulation technology, types and applications toward targeted drug delivery. Nanomedicine. 6:9–24. 2010. View Article : Google Scholar : PubMed/NCBI
8	Nishiyama N and Kataoka K: Current state, achievements and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol Ther. 112:630–648. 2006. View Article : Google Scholar : PubMed/NCBI
9	Torchilin VP: Micellar nanocarriers: Pharmaceutical perspectives. Pharm Res. 24:1–16. 2007. View Article : Google Scholar : PubMed/NCBI
10	Murthy RS and Umrethia ML: Optimization of formulation parameters for the preparation of flutamide liposomes by 3(3) factorial 26-term logit model. Pharm Dev Technol. 9:369–377. 2004. View Article : Google Scholar : PubMed/NCBI
11	Madhusudhan B, Rambhau D, Apte SS and Gopinath D: Oral bioavailability of flutamide from 1-o-alkylglycerol stabilized o/w nanoemulsions. J Disp Sci Technol. 28:1254–61. 2007. View Article : Google Scholar
12	Zeng X, Tao W, Mei L, Huang L, Tan C and Feng SS: Cholic acid-functionalized nanoparticles of star-shaped PLGA-vitamin E TPGS copolymer for docetaxel delivery to cervical cancer. Biomaterials. 34:6058–6067. 2013. View Article : Google Scholar : PubMed/NCBI
13	Thamake SI, Raut SL, Gryczynski Z, Ranjan AP and Vishwanatha JK: Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer. Biomaterials. 33:7164–7173. 2012. View Article : Google Scholar : PubMed/NCBI
14	Hrkach J, Von Hoff D, Ali MM, Andrianova E, Auer J, Campbell T, de Witt D, Figa M, Figueiredo M, Horhota A, et al: Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med. 4:128–39. 2012. View Article : Google Scholar
15	Ganju A, Yallapu MM, Khan S, Behrman SW, Chauhan SC and Jaggi M: Nanoways to overcome docetaxel resistance in prostate cancer. Drug Resist Updat. 17:13–23. 2014. View Article : Google Scholar : PubMed/NCBI
16	Hrkach JI, Von Hoff D, Ali Mukkaram M, Andrianova E, Auer J, Campbell T, De Witt D, Figa M, Figueiredo M, Horhota A, et al: Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med. 4:128ra392012. View Article : Google Scholar : PubMed/NCBI
17	Yallapu MM, Gupta BK, Jaggi M and Chauhan SC: Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells. J Colloid Interface Sci. 351:19–29. 2010. View Article : Google Scholar : PubMed/NCBI
18	Kanfer I: Report on the international workshop on the biopharmaceutics classification system (BCS): Scientific and regulatory aspects in practice. J Pharm Pharm Sci. 5:1–4. 2002.PubMed/NCBI
19	Le Y, Ji H, Chen JF, Shen Z, Yun J and Pu M: Nanosized bicalutamide and its molecular structure in solvents. Int J Pharm. 370:175–180. 2009. View Article : Google Scholar : PubMed/NCBI
20	Meer T, Fule R, Khanna D and Amin P: Solubility modulation of bicalutamide using porous silica. Int J Pharm Invest. 43:279–285. 2013. View Article : Google Scholar
21	Sundaramoorthy P, Baskaran R, Mishra SK, Jeong KY, et al: Novel self-micellizing anticancer lipid nanoparticles induce cell death of colorectal cancer cells. Colloids Surf B Biointerfaces: Biointerfaces. 135:793–801. 2015. View Article : Google Scholar
22	Yallapu MM, Othman SF, Curtis ET, Gupta BK, Jaggi M and Chauhan SC: Multi-functional magnetic nanoparticles for magnetic resonance imaging and cancer therapy. Biomaterials. 32:1890–1905. 2011. View Article : Google Scholar : PubMed/NCBI
23	Solito E, de Coupade C, Canaider S, Goulding NJ and Perretti M: Transfection of annexin 1 in monocytic cells produces a high degree of spontaneous and stimulated apoptosis associated with caspase-3 activation. Br J Pharmacol. 133:217–228. 2001. View Article : Google Scholar : PubMed/NCBI